Actively Recruiting
A Description of the Proportion, Genotype Distribution of Respiratory Syncytial Virus and the Severity of Disease in Hospitalized Elderly in Vietnam
Led by Tam Anh Research Institute · Updated on 2025-11-20
1000
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the proportion and characteristics of Respiratory Syncytial Virus (RSV) infections in adults aged 60 and older who are hospitalized with acute respiratory infections or worsening cardiopulmonary disease. This observational, prospective, multicenter study aims to better understand RSV's impact, including genotype distribution, viral load, co-infections, disease severity, and healthcare use in this elderly population in Vietnam. The study will enroll 1000 participants at two hospitals, where standard care will be given without any experimental treatment. Within 24 hours of consent, nasal and sputum samples will be collected for testing RSV, influenza, and COVID-19 using PCR methods. A subset of samples will undergo advanced genetic sequencing to identify virus types and other pathogens. Data on clinical presentation, treatment, and outcomes will be gathered during hospitalization, with severity assessed by questionnaires and clinical scores. After discharge, participants will be followed by phone for three months to monitor health status and healthcare use such as readmissions and outpatient visits. Researchers will collect detailed demographic, clinical, and laboratory data to analyze factors linked to severe RSV infection. Ethical standards will be maintained, and patient data will be securely handled. The study will provide valuable information to guide RSV prevention and vaccination efforts for older adults in Vietnam.
CONDITIONS
Brief Title
Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged 60 years or older at screening
- Hospitalized with acute respiratory infection or worsening cardiopulmonary disease diagnosed at admission
- Symptoms may include nasal congestion, sore throat, cough, dyspnea, wheezing, hypoxemia, pneumonia, bronchitis, influenza, or respiratory failure
- Agrees to voluntarily participate in the study
You will not qualify if you...
- Symptoms started more than 6 days before screening
- Acute symptoms confirmed unrelated to infection
- Hospital admission within 30 days prior to screening
- Participated in this study within the last 45 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - Up to 6 days from symptom onset
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) at hospital admission
Duration - Within 24 hours after hospital admission
Participants undergo sample collection and diagnostic testing for respiratory viruses including RSV, influenza, and COVID-19 within 24 hours of hospital admission.
1 visit (in-person) for sample collection
Duration - Duration of hospital stay
Participants are observed during hospitalization with data collected on clinical presentation, treatment, and disease severity.
Ongoing assessments during hospitalization
Duration - 3 months post-discharge
Participants are followed up by telephone for three months post-discharge to assess health status and healthcare resource utilization.
Up to 3 telephone calls over 3 months
Trial Site Locations
Total: 1 location
1
Tam Anh TP. Ho Chi Minh General Hospital
Ho Chi Minh City, Southern Vietnam, Vietnam, 700000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here